282 related articles for article (PubMed ID: 37080752)
21. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
22. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting.
Attardi E; Savi A; Borsellino B; Piciocchi A; Cipriani M; Ottone T; Fabiani E; Divona M; Travaglini S; Pascale MR; Awada H; Durmaz A; Visconte V; Della Porta MG; Venditti A; Maciejewski JP; Gurnari C; Voso MT
Blood Adv; 2023 Sep; 7(17):5122-5131. PubMed ID: 37327116
[TBL] [Abstract][Full Text] [Related]
23. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
24. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
25. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
26. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
Venugopal S; Loghavi S
Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
[TBL] [Abstract][Full Text] [Related]
27. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
29. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
[TBL] [Abstract][Full Text] [Related]
30. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms.
Bennett JM
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):607-609. PubMed ID: 27693133
[TBL] [Abstract][Full Text] [Related]
31. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
32. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
Bruehl FK; Osman MM; Chen D; Dalland JC
J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
[TBL] [Abstract][Full Text] [Related]
33. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
34. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
[TBL] [Abstract][Full Text] [Related]
35. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
37. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
38. Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia.
Madarász K; Mótyán JA; Bedekovics J; Miltényi Z; Ujfalusi A; Méhes G; Mokánszki A
Cells; 2022 Nov; 11(21):. PubMed ID: 36359870
[TBL] [Abstract][Full Text] [Related]
39. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
